Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Medicus Pharma Ltd ( (MDCX) ) has issued an update.
Medicus Pharma reported positive topline Phase 2 results from its SKNJCT-003 trial evaluating its Doxorubicin Microneedle Array, branded as SkinJect, for the non-invasive treatment of nodular basal cell carcinoma. In the 200-microgram dose cohort at Day 57, the therapy achieved 73% clinical clearance and 40% histological clearance, outperforming placebo and lower-dose groups.
The company views these results as decision-grade and expects to finalize a full Clinical Study Report in the second quarter of 2026 to support a planned end-of-Phase 2 meeting with the FDA. Management believes the efficacy data, particularly at the higher dose, strengthens Medicus Pharma’s hand in current and future partnering discussions, aligning with its strategy to de-risk programs through Phase 2 and then pursue licensing or strategic partnerships for late-stage development and commercialization.
The most recent analyst rating on (MDCX) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Medicus Pharma Ltd stock, see the MDCX Stock Forecast page.
Spark’s Take on MDCX Stock
According to Spark, TipRanks’ AI Analyst, MDCX is a Neutral.
The score is primarily constrained by weak financial performance (no revenue, widening losses, and heavy cash burn with negative equity) and bearish technicals (price below all major moving averages with negative MACD). Valuation is difficult to assess due to negative earnings and no dividend support, while recent financing provides some liquidity benefit but reinforces dilution/financing dependence.
To see Spark’s full report on MDCX stock, click here.
More about Medicus Pharma Ltd
Medicus Pharma Ltd., traded on Nasdaq as MDCX, is a precision-guided biotech and life sciences company focused on advancing novel, potentially disruptive therapeutic assets through Phase 2 proof-of-concept. The company’s strategy centers on non-invasive treatments such as its Doxorubicin Microneedle Array for skin cancers, with an emphasis on partnering with larger pharmaceutical firms for late-stage development and commercialization.
Average Trading Volume: 419,593
Technical Sentiment Signal: Sell
Current Market Cap: $37.56M
For a thorough assessment of MDCX stock, go to TipRanks’ Stock Analysis page.